NBB, my (off-the-cuff) take on Slide 14 of the presentation.  

1) A 6% royalty stream for all successful indications in ZEN-3694 collaboration with BP (s) or an outright sale of ZEN-3694 to an individual BP.

2) A 6-12 % Resverlogix royalty stream for apabetalone. In this case, apabetalone would need to be licenced to BP(s).

-Or Resverlogix continues with Clinical Trials (COVID/BOM2) if they can get funding, a going-it-alone scenario with royalties funnelled to ZCC. 

-If Apabetalone is sold to a BP don't know how that affects the Royalty stream in favour of ZCC.

Note: In both cases, it would seem that all money goes to ZCC's coffers not directly to shareholders, with dividends potentially, paid out to shareholders.

IMO ... Koo